Latest News of BV
Analysis-BBVA's Sabadell bid mired in concerns over competition and Mexico
By Yahoo! Finance |
2 days ago
BBVA's bid for Sabadell faces delays due to Spanish regulators' phase 2 review, as Trump's election victory raises concerns over BBVA's Mexican business. Uncertainty looms as CNMC's examination may de...
AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials
By Yahoo! Finance |
2 days ago
AbbVie's stock plummeted by 12% after its anti-psychotic drug, emraclidine, failed to meet primary endpoints in Phase II trials for schizophrenia treatment....
Health Care Down as AbbVie, Humana Weigh -- Health Care Roundup
By MarketWatch |
3 days ago
Health-care stocks fell due to concerns over AbbVie and Humana. AbbVie's shares dropped by over 12% following disappointing results from its schizophrenia drug trials. Conversely, Bristol Myers' stock...
-
Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints
By MarketWatch | 3 days agoBristol Myers Squibb's stock rose by 12.5% following AbbVie's announcement of disappointing trial results for their new schizophrenia drug, causing AbbVie's shares to drop by 12.4%....
-
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
By MarketWatch | 3 days agoAbbVie's stock dropped significantly as their schizophrenia drug, emraclidine, failed to show significant improvement in two Phase 2 trials. The drug did not meet the primary endpoint of demonstrating...
-
AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
By Yahoo! Finance | 3 days agoAbbVie Inc. faces a setback as its drug for schizophrenia failed in trials, causing shares to drop significantly. This news benefits Bristol Myers Squibb Co., which recently gained approval for a new ...
-
EBRD approves €25m loan for green investments with GarantiBBVA Leasing
By Yahoo! Finance | 6 days agoThe EBRD has approved a €25 million loan to GarantiBBVA Leasing for green investments in Türkiye. The loan aims to support environmentally sustainable projects, focusing on energy efficiency, renew...
-
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
By Yahoo! Finance | 6 days agoInvestors often rely on analyst recommendations from brokerage firms to make stock decisions. However, these recommendations may not always be reliable due to potential biases. The Zacks Rank, a quant...
-
A top mind at JPMorgan Asset Management sounds the alarm about an obvious economic red flag after Trump's resounding win, even as US stocks soar
By Business Insider | 1 week agoMarkets surged as Donald Trump won the election, boosting US stocks to new highs. JPMorgan strategist David Kelly warns of inflation risks due to potential tax cuts and tariffs, cautioning against the...
-
Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy Right Now?
By Yahoo! Finance | 1 week agoThe pharmaceutical industry is booming, with a focus on innovative research and development. AbbVie Inc. is one of the top pharma stocks to watch. Advances in medical technology and AI are transformin...
-
Those who invested in Bravura Solutions (ASX:BVS) a year ago are up 78%
By Yahoo! Finance | 1 week agoPassive investing in index funds tracks market returns, but picking above-average stocks like Bravura Solutions (ASX:BVS) can lead to higher returns. Despite a recent 78% share price increase, long-te...
-
The minds behind EA Sports FC, NBA 2K, Madden soundtracks seek music from everywhere but the obvious
By The New York Times | 1 week agoSteve Schnur, EA's music president, discovers new artists for video game soundtracks by staying up late, seeking fresh music globally. His team curates diverse tracks to create immersive experiences, ...
-
Compania de Minas Buenaventura SAA (BVN) Q3 2024 Earnings Call Highlights: Record Net Income ...
By Yahoo! Finance | 1 week agoSan Gabriel project is expected to generate $100 million EBITDA annually with $1,300/ounce cash cost. Trapiche project's feasibility study progressing, aiming for significant advancements in six month...
-
AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates
By Yahoo! Finance | 2 weeks agoAbbVie reported quarterly earnings of $3 per share, beating estimates. The company's revenue also exceeded expectations. With a strong performance, investors await management's guidance for future gro...
-
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi
By Investor's Business Daily | 2 weeks agoAbbVie (ABBV) stock rose as it reported Q3 earnings of $3 per share on $14.46 billion in sales, beating analyst estimates. Sales of new drugs Skyrizi and Rinvoq surpassed expectations, with Skyrizi ou...